TAKHZYRO 300 mg
TAKHZYRO 300 mg is a medicine authorised by Swissmedic under authorisation number 70150. The authorisation holder is Takeda Pharma AG. The medicinal product code is Biotechnological medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 19 February 2026 and the authorisation is limited until 18 February 2031. ATC code B06AC05 places the medicine in the group Other hematological agents.
| Authorisation number | 70150 |
|---|---|
| Name | TAKHZYRO 300 mg |
| Full name | TAKHZYRO 300 mg, Injektionslösung im Fertigpen |
| Authorisation holder | Takeda Pharma AG |
| Medicinal product code | Biotechnological medicines |
| Dispensing category | B · Prescription only |
| ATC code | B06AC05 |
| First authorisation | 19 February 2026 |
| Authorisation validity | 18 February 2031 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | TAKHZYRO 300 mg, Injektionslösung im Fertigpen | B | 19 February 2026 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 1 | Fertigpen zu 2 ml | B06AC05 | 02.99.0. | B |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is TAKHZYRO 300 mg authorised in Switzerland?
Yes. TAKHZYRO 300 mg is authorised by Swissmedic under authorisation number 70150, data as of 01 September 2026. The authorisation is limited until 18 February 2031.
Which dispensing category does TAKHZYRO 300 mg have?
TAKHZYRO 300 mg is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of TAKHZYRO 300 mg?
The authorisation holder is Takeda Pharma AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.